Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for Pain Control After Lateral Lumbar Interbody Fusion
NCT05611749Phase 2Terminated
- Sponsor
- Scripps Health
- Start
- May 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute postoperative pain and chronic post-surgical pain (CPSP) comparing Duloxetine Group with Placebo Group (2 arms). Primary endpoints: Change in Postoperative Pain at 10 days, Change in Postoperative Function at 10 days and 9 more. Started May 2023; status: terminated.
02
Drugs
duloxetine
03
Conditions
acute postoperative painchronic post-surgical pain (CPSP)
Beyond the preview
Go deeper on NCT05611749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05611749.